Influenza
Conditions
Brief summary
The increase in influenza vaccine strain-specific serum antibody titers from pre-vaccination (T0) to 28 days (+/- 3 days) post-vaccination (T1) as measured by HI assay.
Detailed description
The increase in influenza-specific T cell responses in PBMCs from pre-vaccination (T0) to 28 days (+/- 3 days) post-vaccination (T1) as measured by ELISpot., Chronotype, assessed via the micro-Munich Chronotype Questionnaire, The incidence of influenza virus infection, as determined by rapid influenza diagnostic self-tests, and self-reported influenza-like illness symptoms up to six months of follow-up.
Interventions
DRUGPNEUMOVAX 23 solution for injection in pre-filled syringe Pneumococcal Polysaccharide Vaccine
DRUGVaxigrip Tetra
DRUGinactivated)
DRUGInfluvac Tetra suspension for injection in pre-filled syringe
(influenza vaccine
DRUGsurface antigen
Sponsors
Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The increase in influenza vaccine strain-specific serum antibody titers from pre-vaccination (T0) to 28 days (+/- 3 days) post-vaccination (T1) as measured by HI assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| The increase in influenza-specific T cell responses in PBMCs from pre-vaccination (T0) to 28 days (+/- 3 days) post-vaccination (T1) as measured by ELISpot., Chronotype, assessed via the micro-Munich Chronotype Questionnaire, The incidence of influenza virus infection, as determined by rapid influenza diagnostic self-tests, and self-reported influenza-like illness symptoms up to six months of follow-up. | — |
Countries
Netherlands
Outcome results
None listed